AbbVie's (ABBV) Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. ASML
2. USO
3. LAD
4. ROIV
5. DKNG
6. BSX
7. ODFL
8. NVS
9. AHR
10. ALV

Go back to AbbVie's (ABBV) Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
AbbVie (NYSE: ABBV) Delayed: 256.46 --0 (-0%)
Previous Close $256.46    52 Week High $68.12 
Open $256.46    52 Week Low $50.71 
Day High $256.46    P/E 55.63 
Day Low $256.46    EPS $4.61 
Volume 4,177